WUXI APPTEC (02359) shares surged 7.51% in Monday's pre-market trading following the release of its impressive third-quarter financial results and an upward revision of its full-year guidance. The company, a leading global pharmaceutical and medical device open-platform capability and technology provider, reported substantial growth in both revenue and net profit for the first three quarters of 2025.

According to the financial report, WUXI APPTEC achieved revenues of 32.86 billion yuan for the first three quarters, representing an 18.6% increase year-over-year. The adjusted Non-IFRS net profit reached 10.55 billion yuan, soaring by 43.4% compared to the same period last year. Notably, the company's Non-IFRS profit margin expanded to 32.1%, a significant improvement of 5.6 percentage points year-over-year.

Investors were particularly encouraged by WUXI APPTEC's strong performance in the third quarter alone. The company reported Q3 revenues of 12.06 billion yuan, marking a 15.3% year-over-year increase and an 8.2% quarter-over-quarter growth. The adjusted Non-IFRS net profit for Q3 stood at 4.22 billion yuan, representing a robust 42.0% year-over-year increase and a 16.1% quarter-over-quarter growth. The Non-IFRS profit margin for Q3 reached an impressive 35.0%, up 6.6 percentage points year-over-year and 2.4 percentage points quarter-over-quarter. In light of these strong results, WUXI APPTEC has raised its full-year revenue growth guidance to 17-18%, up from the previous 13-17%, demonstrating the company's confidence in its continued growth trajectory.